A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

BACKGROUND: Copaxone is an efficacious and safe therapy that has demonstrated clinical benefit for over two decades in patients with relapsing forms of multiple sclerosis (MS). On an individual level, patients show variability in their response to Copaxone, with some achieving significantly higher r...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Genome Med
Main Authors: Ross, Colin J., Towfic, Fadi, Shankar, Jyoti, Laifenfeld, Daphna, Thoma, Mathis, Davis, Matthew, Weiner, Brian, Kusko, Rebecca, Zeskind, Ben, Knappertz, Volker, Grossman, Iris, Hayden, Michael R.
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2017
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5450152/
https://ncbi.nlm.nih.gov/pubmed/28569182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13073-017-0436-y
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares